clinical trial · NCT02944955
A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
BioLite, Inc.·phase2·not yet recruiting·n = 52
Myelodysplastic Syndrome (MDS)BLEX 404 Oral Liquid
brief summary
This is a clinical trial to determine the safety, recommended dose level (RDL), and infection control of BLEX 404 Oral Liquid in combination with azacitidine in patients with International Prognostic Scoring System (IPSS) intermediate-1 (int-1), intermediate-2 (int-2) or high-risk myelodysplastic syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML).
started
Jan 1, 2027
primary completion
Dec 31, 2028
completion
Dec 31, 2028
last updated
Apr 13, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol